{"title":"Design of Synthetic mRNAs for Highly Efficient Translation","authors":"Masahito Inagaki, Mizuki Tada, H. Abe","doi":"10.2745/dds.37.196","DOIUrl":null,"url":null,"abstract":"Recently messenger RNA (mRNA)therapeutics is received much attention as one of the vaccination therapies to compete against the coronavirus disease 2019(COVID-19)pandemic. DDS mRNA therapeutics are generally produced by in vitro transcription utilizing RNA polymerase mediated elongation. However, its purity, stability, and protein synthesis ability, are difficult to be precisely controlled, which is pointed out as drawbacks that must be overcome. To overcome these issues, the introduction of chemically modified nucleic acids is focusing attention. However, it is difficult to flexible molecular design due to the requirement of RNA polymerase recognition ability of chemically modified nucleic acids under in vitro transcription reaction. In the future, the development of a new mRNA design concept based on a flexible molecular design by the progress of chemically modified mRNA therapeutics synthesis method. Under the situation, the authors are focusing on the translation mechanism of mRNA and proposing a new mRNA molecular design to accelerate the translation reaction cycle. In this paper, we introduce an update on therapeutic mRNA design. © 2022, Japan Society of Drug Delivery System. All rights reserved.","PeriodicalId":11331,"journal":{"name":"Drug Delivery System","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Delivery System","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2745/dds.37.196","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
用于高效翻译的合成信使核糖核酸的设计
最近,信使RNA(mRNA)疗法作为对抗2019冠状病毒病(新冠肺炎)大流行的疫苗接种疗法之一受到了广泛关注。DDSMRNA治疗剂通常通过利用RNA聚合酶介导的延伸的体外转录产生。然而,它的纯度、稳定性和蛋白质合成能力很难精确控制,这被指出是必须克服的缺点。为了克服这些问题,化学修饰核酸的引入引起了人们的关注。然而,由于化学修饰核酸在体外转录反应下对RNA聚合酶的识别能力的要求,很难进行灵活的分子设计。未来,通过化学修饰信使核糖核酸疗法合成方法的进展,开发出一种基于柔性分子设计的新信使核糖核酸设计概念。在这种情况下,作者专注于信使核糖核酸的翻译机制,并提出了一种新的信使核糖核酸分子设计来加速翻译反应周期。在本文中,我们介绍了治疗性信使核糖核酸设计的最新进展。©2022,日本药物输送系统学会。保留所有权利。
本文章由计算机程序翻译,如有差异,请以英文原文为准。